Comparative Pharmacology
Head-to-head clinical analysis: CORDRAN SP versus HC 1.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORDRAN SP versus HC 1.
CORDRAN SP vs HC #1
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Topical corticosteroid that induces phospholipase A2 inhibitory proteins (lipocortins), inhibiting arachidonic acid release and subsequent prostaglandin and leukotriene synthesis, thereby mediating anti-inflammatory, antipruritic, and vasoconstrictive effects.
Unknown
Apply a thin film to the affected area 1 to 2 times daily. Use the smallest amount for adequate therapy. Do not use for more than 2 weeks per course of treatment.
Hydrocortisone: 100-200 mg IV as initial dose, then 50-100 mg IV every 6 hours, or 0.18 mg/kg/h IV continuous infusion.
None Documented
None Documented
Terminal half-life approximately 48 hours; prolonged with hepatic impairment.
2–4 hours (terminal); prolonged in renal impairment.
Primarily renal as inactive metabolites; <5% unchanged. Minimal biliary/fecal elimination.
Renal: 90% as unchanged drug; fecal: 10%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid